Vaccine Responses in Patients with Rheumatoid Arthritis Treated with Certolizumab Pegol: Results from a Single-blind Randomized Phase IV Trial

201478 citationsJournal Articlebronze Open Access

Authors

Alan Kivitz · Altoona Center for Clinical Research

Joy Schechtman

Michele Texter · UCB Pharma (Germany)

Andreas Fichtner · UCB Pharma (United States)

M. de Longueville · UCB Pharma (Belgium)

Elliot Chartash · UCB Pharma (Germany)

Abstract

Humoral immune responses to pneumococcal and influenza vaccination are not impaired when given during the loading phase of CZP treatment in patients with RA. (ClinicalTrials.gov NCT00993668).

Topics & Keywords

Rheumatoid Arthritis Research and Therapies Monoclonal and Polyclonal Antibodies Research Immunodeficiency and Autoimmune Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Journal of Rheumatology

Volume 41, Issue 4, pp. 648-657

DOI: 10.3899/jrheum.130945

Field-Weighted Citation Impact: 4.74